Brief: Solid Biosciences Announces Positive Feedback From Type C Meeting With FDA For Sgt-003 Gene Therapy For Duchenne Muscular Dystrophy

Solid Biosciences

09/02/2026 14:57

Feb 9 (Reuters) - Solid Biosciences Inc SLDB.O:

SOLID BIOSCIENCES ANNOUNCES POSITIVE FEEDBACK FROM TYPE C MEETING WITH FDA FOR SGT-003 GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY

SOLID BIOSCIENCES INC: COMPANY PLANS FOR ADDITIONAL MEETINGS WITH FDA IN 1H 2026

SOLID BIOSCIENCES INC - ALIGNS WITH FDA ON PHASE 3 TRIAL DESIGN

SOLID BIOSCIENCES INC - FIRST PARTICIPANT DOSING EXPECTED IN Q1 2026

SOLID BIOSCIENCES INC - SGT-003 WELL TOLERATED IN PHASE 1/2 TRIAL WITH 36 DOSED AS OF FEB 9

Source text: ID:nGNX4m8RNK

Further company coverage: SLDB.O

 ((Reuters.Briefs@thomsonreuters.com;))